Navigation Links
Dynavax Issued Landmark Patent Covering Second-Generation TLR9 Agonists
Date:8/19/2007

BERKELEY, Calif., Aug. 16 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) today announced that the U.S. Patent Office has issued the company a broad composition of matter patent covering the company's proprietary second-generation TLR9 agonists.

The claims cover a broad class of novel TLR9 agonists containing short DNA sequences separated by spacer molecules. These linear chimeric immunomodulatory compounds (CICs), are being developed at Dynavax for application across a wide range of therapeutic categories. The claims cover CICs with or without antigen, and alone or in a pharmaceutical preparation. The current term for this patent expires in June 2022. The patent, U.S. patent No. 7,255,868 B2, was issued August 14, 2007 with inventors Karen Fearon, Dino Dina, M.D., and Stephen Tuck.

According to Dino Dina, M.D., President and Chief Executive Officer, "We developed the second-generation TLR9 agonists specifically to gain broad patent coverage for a full range of products in our pipeline. The issuance of this landmark patent provides broad patent coverage for novel and non-obvious molecules that are completely different from our first generation TLR9 agonists. We have pending applications in this family that we believe have the potential to expand the scope of coverage."

About Dynavax

Dynavax Technologies Corporation discovers, develops, and intends to commercialize innovative TLR9 agonist-based products to treat and prevent infectious diseases, allergies, cancer, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Our TLR9 agonists are based on immunostimulatory sequences, or ISS, which ar
'/>"/>

SOURCE Dynavax Technologies Corporation

Copyright©2007 PR Newswire.

Page: 1 2

Related biology technology :

1. Landmark patent law under attack, Bayh says
2. Changes to U.S. patent law must nurture our culture of innovation
3. WARF questions relevancy of documents used to uphold patent challenge
4. Supreme Court limits foreign reach of U.S. patents
5. High court sends message on patent obviousness
6. Supreme Court ruling seen as blow to WARF stem cell patents
7. Patent licensing: For enforcing companies, the rules have changed
8. Patent ruling doesnt tarnish Wisconsins stem cell leadership
9. Heres why Wisconsins stem cell patents are being challenged
10. WARF is likely to hold on to stem cell patent rights
11. Patent office upholds challenge to WARF stem cell patents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... CAMBRIDGE, Mass. , April 21, 2015 ... clinical data from a multi-arm Phase 1 study of ... data were presented in an oral session by Dr. ... Association for Cancer Research Annual Meeting in ... and tolerability of MM-141 as a monotherapy and in ...
(Date:4/21/2015)... 2015 Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) ... on Thursday, April 23, 4:30 p.m. ET. Participants are ... Investor call information: U.S./ ... toll number: (925) 418-7845 Participant Passcode: 32888538 ... Amirkiai , tina.amirkiai@fleishman.com . Access will ...
(Date:4/21/2015)... Calif. , April 21, 2015 /PRNewswire/ ... provider of advanced cryogenic logistics solutions for ... immunotherapies, stem cells, cell lines, clinical research ... announced that Dr. Mark W. Sawicki ... the 3rd Annual BioLogistics Summit in ...
(Date:4/21/2015)... Mass. , April 21, 2015 /PRNewswire/ ... developing transformative pharmaceutical products for subcutaneous delivery, ... pivotal trial of its investigational proprietary drug ... of edema associated with congestive heart failure. ... scPharmaceuticals is developing a proprietary patch pump.  ...
Breaking Biology Technology:First-in-Human Phase 1 Trial of MM-141 Demonstrates Activity in Biomarker Positive Patients 2First-in-Human Phase 1 Trial of MM-141 Demonstrates Activity in Biomarker Positive Patients 3First-in-Human Phase 1 Trial of MM-141 Demonstrates Activity in Biomarker Positive Patients 4First-in-Human Phase 1 Trial of MM-141 Demonstrates Activity in Biomarker Positive Patients 5Ampio Announces Investor Call on Thursday, April 23, 4:30 p.m. ET 2Cryoport to Present at the 3rd Annual BioLogistics Summit in San Francisco, CA 2Cryoport to Present at the 3rd Annual BioLogistics Summit in San Francisco, CA 3scPharmaceuticals Announces Start of Pivotal Trial for Novel Furosemide Solution for Subcutaneous Delivery 2scPharmaceuticals Announces Start of Pivotal Trial for Novel Furosemide Solution for Subcutaneous Delivery 3
... ET; 8:00 a.m. PT, VANCOUVER and SAN DIEGO, ... a clinical-stage developer of drugs for infectious,diseases, will host ... at 11:00 a.m. ET (8:00 a.m. PT) to discuss ... 2008 and provide an update on,company activities. To participate ...
... on Detroit Area, DETROIT, March 11 ... its new study, Affordable Broadband:,Empowering Communities Across the ... to education, health care and civic,involvement in minority ... Empowerment Council (DEC) that was launched,earlier this year ...
... March 11 Haemonetics,Corporation announced today the appointment ... Chief Marketing Officer. In this position, Mr. Allen,will ... portfolio in addition to his current responsibilities as ... commented, "Pete Allen was an,architect of our strategic ...
Cached Biology Technology:Study Finds Broadband Access Key to Empowerment of Minority Communities 2Haemonetics(R) Appoints Peter Allen as Chief Marketing Officer 2
(Date:4/1/2015)... Apr. 1, 2015  NXT-ID, Inc. (NASDAQ: NXTD ... focused on the growing mobile commerce market, announces the ... wallets is underway to early access pre-order customers. ... usage at retail outlets including Walmart, Target, AT&T, Dunkin, ... Wocket was accepted at all outlets and very easy ...
(Date:3/31/2015)... , March 31, 2015   Guidepoint , ... launch of the Post-Surgical Pain Management TRACKER, part of ... tracking usage trends in the medical device and therapeutics ... to data including treatment volumes, market share, and adoption ... pain associated with joint surgery. The Post-Surgical ...
(Date:3/24/2015)... 24, 2015 Research and Markets ( ... "Global Iris Recognition Market 2015-2019" report to their ... Recognition market to grow at a CAGR of 23.5 ... covers the present scenario and the growth prospects of ... To calculate the market size, the report considers the ...
Breaking Biology News(10 mins):NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2
... the next big innovation in sustainable climate technology? ... for Business Law and Regulation at Case Western Reserve ... do just that. "Technology-induced prizes have a long ... on a Climate Prize Rewarding Energy Innovation to Achieve ...
... ST. AUGUSTINE, TRINIDAD AND TOBAGOFlower color in plants ... carotenoids. Research has found that the ultimate color displayed ... also on other factors, including cell shape, presence of ... role of pH in creating color has allowed plant ...
... Ill. Researchers have identified a protein long known to ... growth. Their study, in the journal Oncogene , is ... accomplishes this feat. "People suggested that Runx3 might be ... it is down-regulated in a lot of breast cancer cell ...
Cached Biology News:CWRU law professor eyes prize-based incentives to generate climate innovation 2Engineering blue-hued flowers 2Team identifies new breast cancer tumor suppressor and how it works 2
... ( Abpromise for all tested ... Synthetic peptide derived from within residues ... MSY2/YBOX2. (Note: the amino acid ... (Peptide available as ab27460 .) ...
Request Info...
Molecular Biology grade. Ideally suited for DNA and RNA separation and recovery. High gel strength. Gelling temp. 36C. Melting temp. 88C. EEO: 0.05-0.13 Resolution 0.2-40 kb; Rnase/Dnase: none detec...
... Signet offers the most comprehensive, ... requirements. We have incorporated unprecedented quality ... capabilities. This includes proven detection chemistries ... to the TechMate protocol. It also ...
Biology Products: